Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain

Background and Purpose Available medications for chronic pain provide only partial relief and often cause unacceptable side effects. There is therefore a need for novel molecular targets to develop new therapeutics with improved efficacy and tolerability. Despite encouraging efficacy data in rodents...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of pharmacology 2013-11, Vol.170 (5), p.1053-1063
Hauptverfasser:	Mingorance‐Le Meur, A, Ghisdal, P, Mullier, B, De Ron, P, Downey, P, Van Der Perren, C, Declercq, V, Cornelis, S, Famelart, M, Van Asperen, J, Jnoff, E, Courade, J P
Format:	Artikel
Sprache:	eng
Schlagworte:	Analgesics - pharmacology Analgesics - toxicity Animals Benzamides - pharmacology Benzamides - toxicity Blood-Brain Barrier - drug effects Blood-Brain Barrier - metabolism Brain - drug effects Brain - metabolism Brain - physiopathology Capillary Permeability Cell Line Disease Models, Animal Dose-Response Relationship, Drug Drug therapy Formaldehyde glycine Glycine Agents - pharmacology Glycine Agents - toxicity Glycine Plasma Membrane Transport Proteins - antagonists & inhibitors Glycine Plasma Membrane Transport Proteins - metabolism Humans Medical research Membrane Potentials Mice neuropathic pain pain Pain - chemically induced Pain - metabolism Pain - physiopathology Pain - prevention & control Pain management Pain Measurement Pain Threshold - drug effects Research Papers reversible inhibitor Serine - analogs & derivatives Serine - pharmacology Serine - toxicity Toxicity Transfection Xenopus laevis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!